Teva R&D Chief and Chief Medical Officer Eric Hughes to Leave; Company Starts Search for Successor
Teva Pharmaceutical Industries said Wednesday that Eric Hughes, its head of global research and development and chief medical officer, is leaving the company, according to an 8-K.
Hughes, an executive vice president, has accepted an offer outside Teva and will stay through the coming months to support the transition, the company said in a press release filed with the 8-K.
Effective immediately, David Gardiner, Teva's head of innovative medicines and clinical development, will serve as transition lead for R&D. He will report directly to President and CEO Richard Francis until a permanent successor is named. Teva said it has started a search for a successor.
Strategy unchanged, Teva says
Teva said its R&D strategy and priorities remain the same and that it remains focused on the commitments it laid out at its Nov. 11 R&D Day. Those include an ambition to generate $6 billion to $7 billion in innovative medicines revenue by 2030, according to the release.
"Our strategy, priorities and expectations have not changed," Francis said in the release. He said Hughes "helped build the pipeline, capabilities, and organization we presented at R&D Day last week."
By the numbers
- Departing: Eric Hughes, EVP, global R&D and chief medical officer
- Interim R&D lead: David Gardiner
- 2030 innovative medicines revenue ambition: $6 billion to $7 billion
Sources
- Form 8-K (Exhibit 99.1), Teva Pharmaceutical Industries Ltd., R&D leadership transition, filed Nov. 18, 2026, accession 0001193125-26-467276
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.